Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 10/20 | 0.37 |
| ▸ | CA1 | P00915 | 10/20 | 0.37 |
| ▸ | CA2 | P00918 | 10/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | APAF1 | O14727 | 3/20 | 0.35 |
| ▸ | CASP3 | P42574 | 3/20 | 0.35 |
| ▸ | CASP9 | P55211 | 3/20 | 0.35 |
| ▸ | CYCS | P99999 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700838 | 0.92 | APAF1 (0.36) | APAF1CASP3CASP9CYCSMAPT | |
| SCHEMBL3704033 | 0.90 | APAF1 (0.36) | CA12CA1CA2CA9APAF1 | |
| SCHEMBL3706919 | 0.89 | APAF1 (0.43) | CA12CA1CA2CA9APAF1 | |
| SCHEMBL3698185 | 0.88 | MAPT (0.36) | APAF1CASP3CASP9CYCSMAPT | |
| SCHEMBL3705971 | 0.88 | GLA (0.39) | APAF1CASP3CASP9CYCSMAPT | |
| SCHEMBL5955934 | 0.86 | CA1 (0.41) | CA12CA1CA2CA9APAF1 | |
| SCHEMBL3696385 | 0.86 | PTGS2 (0.37) | CA12CA1CA2CA9APAF1 | |
| SCHEMBL3693162 | 0.85 | MAPT (0.37) | APAF1CASP3CASP9CYCSMAPT | |
| SCHEMBL3697463 | 0.85 | OPRM1 (0.43) | MAPTALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL3708029 | 0.84 | MAPT (0.35) | APAF1CASP3CASP9CYCSMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040701-B2 | Apaf-1 inhibitor compounds | LABORATORIOS SALVAT, S.A. (ES) | 2015-05-26 | — | — | US | disclosed |
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | LABORATORIOS SALVAT, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | APAF1, API5, AIFM1 | CA12 4687/4885CA1 1810/4885CA2 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.